Skip to main content

Advertisement

SpringerLink
Log in

Successful treatment of brain metastases from renal cell cancer using radiotherapy in combination with sorafenib

  • Day-to-Day Practice
  • Published:
Targeted Oncology Aims and scope Submit manuscript

Abstract

Sorafenib, an antiangiogenic drug, has been introduced for treatment of disseminated renal cell cancer (RCC), a tumor that is radioresistant. We report a case of 51-year-old patient with disseminated RCC who received 30 Gy per ten fractions of radiotherapy (RT) for a single brain metastasis. While the brain metastasis remained stable, the patient had to receive interferon-alpha and later sorafenib due to progression of his extra-cerebral metastases. During sorafenib therapy, complete remission of the cerebral lesion and excellent partial remission of the extra-cerebral metastases were observed. Meanwhile, the patient developed a second cerebral metastasis, which was irradiated only with 20 Gy per ten fractions during a short break in the sorafenib treatment. The follow-up computed tomographies revealed complete remission of the second metastasis and development of brain necrosis in a moderately irradiated area. The case of this patient being his own control demonstrates sorafenib-mediated potentiation of RT effects both in tumor and normal tissues.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Gupta VK, Jaskowiak NT, Beckett MA et al (2002) Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J 8:47–54

    Article  PubMed  Google Scholar 

  2. Brieger J, Kattwinkel J, Berres M et al (2007) Impact of vascular endothelial growth factor release on radiation resistance. Oncol Rep 18:1597–1601

    PubMed  CAS  Google Scholar 

  3. Plastaras JP, Kim SH, Liu YY et al (2007) Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res 67:9443–9454

    Article  PubMed  CAS  Google Scholar 

  4. Lee CG, Heijn M, di Tomaso E et al (2000) Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60:5565–5570

    PubMed  CAS  Google Scholar 

  5. Gay HA, Cavalieri R, Allison RR et al (2007) Complete response in a cutaneous facial metastatic nodule from renal cell carcinoma after hypofractionated radiotherapy. Dermatol Online J 13:6

    PubMed  Google Scholar 

Download references

Conflict of interest statement

Although the authors have not received and will not receive benefits for personal or professional use from a commercial party related directly or indirectly to the subject of this manuscript, benefits have been received but are directed solely to a research fund. This work was sponsored by an unrestricted research grant from Bayer AB.

Author information

Authors and Affiliations

  1. Department of Oncology, Sahlgrenska University Hospital, 413 45, Gothenburg, Sweden

    Ulrika Stierner & Zahra Taheri-Kadkhoda

Authors
  1. Ulrika Stierner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zahra Taheri-Kadkhoda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulrika Stierner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stierner, U., Taheri-Kadkhoda, Z. Successful treatment of brain metastases from renal cell cancer using radiotherapy in combination with sorafenib. Targ Oncol 3, 259–264 (2008). https://doi.org/10.1007/s11523-008-0091-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-008-0091-8

Keywords

Search

Navigation